Knowledge Library

Pioneering Advanced Modalities in Early Drug Discovery

New modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving needs, WuXi Biology has proactively developed a broad range of capabilities, offering integrated solutions to global pharmaceutical and biotech companies for challenging targets. We have established major capabilities for new modalities in the early discovery …Read More >

Resource Type: Article
Resource Topic: Antibody Drug Conjugate CAR-T Cell Cell Therapies DNA-Encoded Library (DEL) Fragment-Based Drug Discovery Gene Therapies Oligonucleotides Oncolytic Viruses Targeted Protein Degradation

VIEW

Control of the Antitumor Activity and Specificity of CAR T Cells via Organic Adapters Covalently Tethering the CAR to Tumor Cells

On-target, off-tumor toxicity is a specific type of toxic side effect that limits the anticancer applicability of chimeric antigen receptor (CAR) T cells. In our latest publication, WuXi AppTec scientists contributed to a study describing how the tumor-targeting specificity and activity of T cells with a CAR (consisting of an antibody that catalytically forms a …Read More >

Resource Type: Latest Science Publication
Resource Topic: CAR-T Cell Oncology

VIEW

Discovery Newsletter November 2022

Resource Type: Latest Science Newsletter
Resource Topic: CAR-T Cell Cell-based Assays Chemical Biology and Proteomics Discovery Chemistry DRUG DISCOVERY AND INNOVATION in vitro biology Oligonucleotides Oncolytic Viruses Safety and Early Toxicity Small Molecules Target Identification and Validation Target-Specific Assays

VIEW

PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

Resource Type: Latest Science Poster
Resource Topic: Antibodies Biomarkers CAR-T Cell Cell Therapies Cell-based Assays Cells and Protein Science Oncology Target Identification and Validation

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Resource Type: Brochure
Resource Topic: Antibodies Antibody Drug Conjugate Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Biophysical Assays Candidate Selection CAR-T Cell Cardiovascular & Metabolic Diseases Cell Therapies Cell-based Assays Cells and Protein Science Central Nervous System & Pain Chemical Biology and Proteomics Dermatology Discovery Chemistry DNA-Encoded Library (DEL) DRUG DISCOVERY AND INNOVATION Fragment-Based Drug Discovery Gene Therapies High-throughput screening (HTS) Hit Finding Hit-to-Lead Immunology in silico services in vitro biology in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Liver Diseases Mass Spectrometry-based Assays Metabolic Diseases NASH Oligonucleotides Oncology Oncolytic Viruses Ophthalmology Phenotypic Assays Quantum Mechanics Rare Diseases Respiratory Diseases Safety and Early Toxicity Screening Libraries Screening Services Small Molecules Structural Biology Target Identification and Validation Target-Specific Assays Targeted Protein Degradation TECHNOLOGY PLATFORMS THERAPEUTIC AREAS THERAPEUTIC MODALITIES Tumor Models

VIEW

Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond

INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) As a self-proclaimed drug hunter, Phil Jones is on a mission to identify the next generation of cancer medicines that improve the lives of patients with cancer. He leads a multi-disciplinary team of scientists at The University of Texas MD Anderson Cancer Center’s Institute …Read More >

Resource Type: Article
Resource Topic: Biomarkers CAR-T Cell Cells and Protein Science Chemical Biology and Proteomics DRUG DISCOVERY AND INNOVATION Hit Finding in vitro biology in vivo Pharmacology Oncology Phenotypic Assays Small Molecules Target Identification and Validation

VIEW

Virology and Viral Vector Platforms

WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy clinical virology Liver-specific viruses | Respiratory viruses | Herpes viruses | Other viruses

Resource Type: Brochure
Resource Topic: Biochemical Assays Biomarkers Candidate Selection CAR-T Cell Cell-based Assays Cells and Protein Science in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Oncolytic Viruses Phenotypic Assays Safety and Early Toxicity

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!